Browsing by Author "Ansotegui, I"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2)
    Bousquet, J; Pham-Thi, N; Bedbrook, A; Agache, I; Annesi-Maesano, I; Ansotegui, I; Anto, JM; Bachert, C; Benveniste, S; Bewick, M; Billo, N; Bosnic-Anticevich, S; Bosse, I; Brusselle, G; Calderon, MA; Canonica, GW; Caraballo, L; Cardona, V; Carriazo, AM; Cash, E; Cecchi, L; Chu, DK; Colgan, E; Costa, E; Cruz, AA; Czarlewski, W; Durham, S; Ebisawa, M; Erhola, M; Fauquert, JL; Fokkens, WJ; Fonseca, JA; Guldemond, N; Iinuma, T; Illario, M; Klimek, L; Kuna, P; Kvedariene, V; Larenas-Linneman, D; Laune, D; Le, LTT; Lourenço, O; Malva, JO; Marien, G; Menditto, E; Mullol, J; Münter, L; Okamoto, Y; Onorato, GL; Papadopoulos, NG; Perala, M; Pfaar, O; Phillips, A; Phillips, J; Pinnock, H; Portejoie, F; Quinones-Delgado, P; Rolland, C; Rodts, U; Samolinski, B; Sanchez-Borges, M; Schünemann, HJ; Shamji, M; Somekh, D; Togias, A; Toppila-Salmi, S; Tsiligianni, I; Usmani, O; Walker, S; Wallace, D; Valiulis, A; Van der Kleij, R; Ventura, MT; Williams, S; Yorgancioglu, A; Zuberbier, T
  • No Thumbnail Available
    Item
    Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence
    Bousquet, J; Schünemann, HJ; Togias, A; Bachert, C; Erhola, M; Hellings, PW; Klimek, L; Pfaar, O; Wallace, D; Ansotegui, I; Agache, I; Bedbrook, A; Bergmann, KC; Bewick, M; Bonniaud, P; Bosnic-Anticevich, S; Bossé, I; Bouchard, J; Boulet, LP; Brozek, J; Brusselle, G; Calderon, MA; Canonica, WG; Caraballo, L; Cardona, V; Casale, T; Cecchi, L; Chu, DK; Costa, EM; Cruz, AA; Czarlewski, W; D'Amato, G; Devillier, P; Dykewicz, M; Ebisawa, M; Fauquert, JL; Fokkens, WJ; Fonseca, JA; Fontaine, JF; Gemicioglu, B; van Wijk, RG; Haahtela, T; Halken, S; Ierodiakonou, D; Iinuma, T; Ivancevich, JC; Jutel, M; Kaidashev, I; Khaitov, M; Kalayci, O; Tebbe, JK; Kowalski, ML; Kuna, P; Kvedariene, V; La Grutta, S; Larenas-Linemann, D; Lau, S; Laune, D; Le, L; Lieberman, P; Carlsen, KCL; Lourenço, O; Marien, G; Carreiro-Martins, P; Melén, E; Menditto, E; Neffen, H; Mercier, G; Mosgues, R; Mullol, J; Muraro, A; Namazova, L; Novellino, E; O'Hehir, R; Okamoto, Y; Ohta, K; Park, HS; Panzner, P; Passalacqua, G; Nhan, PT; Price, D; Roberts, G; Roche, N; Rolland, C; Rosario, N; Ryan, D; Samolinski, B; Sanchez-Borges, M; Scadding, GK; Shamji, MH; Sheikh, A; Bom, AMT; Toppila-Salmi, S; Tsiligianni, I; Valentin-Rostan, M; Valiulis, A; Valovirta, E; Ventura, MT; Walker, S; Waserman, S; Yorgancioglu, A; Zuberbier, T
    The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm.
  • No Thumbnail Available
    Item
    2019 ARIA Care pathways for allergen immunotherapy
    Bousquet, J; Pfaar, O; Togias, A; Schünemann, HJ; Ansotegui, I; Papadopoulos, NG; Tsiligianni, I; Agache, I; Anto, JM; Bachert, C; Bedbrook, A; Bergmann, KC; Bosnic-Anticevich, S; Bosse, I; Brozek, J; Calderon, MA; Canonica, GW; Caraballo, L; Cardona, V; Casale, T; Cecchi, L; Chu, D; Costa, E; Cruz, AA; Czarlewski, W; Durham, SR; Du Toit, G; Dykewicz, M; Ebisawa, M; Fauquert, JL; Fernandez-Rivas, M; Fokkens, WJ; Fonseca, J; Fontaine, JF; van Wijk, RG; Haahtela, T; Halken, S; Hellings, PW; Ierodiakonou, D; Iinuma, T; Ivancevich, JC; Jacobsen, L; Jute, M; Kaidashev, I; Khaitov, M; Kalayci, O; Tebbe, JK; Klimek, L; Kowalski, ML; Kuna, P; Kvedariene, V; La Grutta, S; Larenas-Linemann, D; Lau, S; Laune, D; Le, L; Carlsen, KL; Lourenço, O; Malling, HJ; Marien, G; Menditto, E; Mercier, G; Mullol, J; Muraro, A; O'Hehir, R; Okamoto, Y; Pajno, GB; Park, HS; Panzner, P; Passalacqua, G; Pham-Thi, N; Roberts, G; Pawankar, R; Rolland, C; Rosario, N; Ryan, D; Samolinski, B; Sanchez-Borges, M; Scadding, G; Shamji, MH; Sheikh, A; Sturm, GJ; Bom, AT; Toppila-Salmi, S; Valentin-Rostan, M; Valiulis, A; Valovirta, E; Ventura, MT; Wahn, U; Walker, S; Wallace, D; Waserman, S; Yorgancioglu, A; Zuberbier, T
    Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients.
  • No Thumbnail Available
    Item
    Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
    Klimek, L; Jutel, M; Akdis, C; Bousquet, J; Akdis, M; Bachert, C; Agache, I; Ansotegui, I; Bedbrook, A; Bosnic-Anticevich, S; Canonica, GW; Chivato, T; Cruz, AA; Czarlewski, W; Del Giacco, S; Du, H; Fonseca, JA; Gao, YD; Haahtela, T; Hoffmann-Sommergruber, K; Ivancevich, JC; Khaltaev, N; Knol, EF; Kuna, P; Larenas-Linnemann, D; Melén, E; Mullol, J; Naclerio, R; Ohta, K; Okamoto, Y; O'Mahony, L; Onorato, GL; Papadopoulos, NG; Pawankar, R; Pfaar, O; Samolinski, B; Schwarze, J; Toppila-Salmi, S; Shamji, MH; Ventura, MT; Valiulis, A; Yorgancioglu, A; Matricardi, P; Zuberbier, T
    The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
  • No Thumbnail Available
    Item
    Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases
    Bousquet, J; Nhân, PT; Bedbrook, A; Agache, I; Annesi-Maesano, I; Ansotegui, I; Anto, JM; Bachert, C; Benveniste, S; Bewick, M; Billo, N; Bosnic-Anticevich, S; Bosse, I; Brusselle, G; Calderon, MA; Canonica, GW; Caraballo, L; Cardona, V; Carriazo, AM; Cash, E; Cecchi, L; Chu, DK; Colgan, E; Costa, E; Cruz, AA; Czarlewski, W; Durham, S; Ebisawa, M; Erhola, M; Fauquert, JL; Fokkens, WJ; Fonseca, JA; Guldemond, N; Iinuma, T; Illario, M; Klimek, L; Kuna, P; Kvedariene, V; Larenas-Linneman, D; Laune, D; Le, LTT; Lourenço, O; Malva, JO; Marien, G; Menditto, E; Mullol, J; Münter, L; Okamoto, Y; Onorato, GL; Papadopoulos, NG; Perala, M; Pfaar, O; Phillips, A; Phillips, J; Pinnock, H; Portejoie, F; Quinones-Delgado, P; Rolland, C; Rodts, U; Samolinski, B; Sanchez-Borges, M; Schünemann, HJ; Shamji, M; Somekh, D; Togias, A; Toppila-Salmi, S; Tsiligianni, I; Usmani, O; Walker, S; Wallace, D; Valiulis, A; Van der Kleij, R; Ventura, MT; Williams, S; Yorgancioglu, A; Zuberbier, T